We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

3 hedge funds and large institutions have $55K invested in Benitec Biopharma in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.19% less ownership

Funds ownership: 0.5% → 0.31% (-0.19%)

40% less funds holding

Funds holding: 5 → 3 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

72% less capital inflows, than outflows

Capital inflows: $11.2K | Capital outflows: $40.7K

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$5.87K
2
Bank of America
Bank of America
North Carolina
+$5.34K

Top Sellers

Rank Fund Capital Flow
1
Wedbush Securities
Wedbush Securities
California
-$18.7K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$8K
3
Deutsche Bank
Deutsche Bank
Germany
-$1K

BNTC Hedge Fund Activity: Q3 2017 in Review

3 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2017, worth a combined $55K — down 26% from $74K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BNTC and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $5.87K. The largest seller was Wedbush Securities, cutting an estimated $18.7K.

  • 3 institutional investors held Benitec Biopharma (BNTC) as of Q3 2017, down from 5 in Q2 2017.
  • Funds reported $55K of Benitec Biopharma stock for Q3 2017, down 26% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q3 2017 and 3 closed out, a net change of -2 holders.
  • The largest Benitec Biopharma buyer in Q3 2017 was UBS Group, an estimated $5.87K added.
  • The largest Benitec Biopharma seller in Q3 2017 was Wedbush Securities, an estimated $18.7K sold.

Based on aggregated 13F filings for Q3 2017.